Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellisept mucosa vs Octenisept for genital mucosal antisepsis
2006-000063-28Phase 3Completed
- Sponsor
- BODE Chemie
- Start
- Mar 2006
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of octenidine in Genital mucosa infection (GMI) and bacterial colonization (2 arms), sponsored by BODE Chemie. Primary endpoints: Antimicrobial efficacy and Local tolerability. Started Mar 2006; status: completed.
02
Drugs
octenidine
03
Conditions
Genital mucosa infection (GMI)bacterial colonization
Beyond the preview
Go deeper on 2006-000063-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000063-28.